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Abstract 
Significant efforts have been made recently to improve data throughput and data quality in 
screening technologies related to drug design. The modern pharmaceutical industry relies heavily 
on high-throughput screening (HTS) and high-content screening (HCS) technologies, which 
include small molecule, complementary DNA (cDNA) and RNA interference (RNAi) types of 
screening. Data generated by these screening technologies are subject to several environmental 
and procedural systematic biases which introduce errors into the hit identification process. We 
first review systematic biases typical of HTS and HCS screens. We highlight that study design 
issues and the way in which data are generated are crucial for providing unbiased screening 
results. Considering various data sets, including the publicly available ChemBank data, we 
assess the rates of systematic bias in experimental HTS by using plate-specific and assay-specific 
error detection tests. We describe main data normalization and correction techniques and 
introduce a general data pre-processing protocol. This protocol can be recommended for 
academic and industrial researchers involved in the analysis of current or next generation high-
throughput screening data. 
 
Keywords: data correction methods, data normalization methods, high-content screening (HCS), 
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INTRODUCTION 
 
There has been a growing interest in the development of high-throughput screening technologies 
over the last few decades [1], largely because screening methods promoted by the 
pharmaceutical industry have played a key role in drug discovery. The increasing computing 
power and miniaturization of screening equipment now allow for carrying out high-throughput 
screening analyses even in small academic laboratories. The most popular screening 
technologies used in drug design are high-content screening (HCS) [2] and high-throughput 
screening (HTS) [3]. Their different subcategories include small molecule [4], complementary 
DNA (cDNA) [5] and RNA interference (RNAi) [6] types of screening. In a typical HCS or HTS 
campaign, hundreds of terabytes of experimental data concerning molecule activity, specificity, 
and physiological and toxicological properties can be generated. These data should be processed 
using appropriate data mining and statistical methods and protocols in order to identify 
promising drug candidates (i.e., hits). One of the key challenges that needs to be answered during 
the analysis of HCS and HTS data is the identification and successful elimination of bias (i.e., 
systematic error) in the measurements. In this review, we discuss the existing types of bias 
common to all high-throughput screening technologies and discuss their negative impact on the 
hit selection process. We underline the necessity of randomization of screened samples and 
indicate the advantages of using replicate measurements. We present the methods intended to 
detect systematic error and those designed to correct the data affected by it. We argue that the 
latter methods should be applied only when the presence of a specific type of systematic error in 
the data has been confirmed by a suitable statistical test [7]. Furthermore, we provide 
suggestions concerning which data normalization and correction techniques should be applied in 
various practical situations. Finally, we present a broad-spectrum data pre-processing protocol 
that can be used for the correction and analysis of screening data prior to assay quality estimation 
and hit selection steps. This protocol can also be used for detecting and removing bias in future 
HTS technologies involving sequential screening of multiple plates. To illustrate the results of 
our analyses, we examine publically available HTS and HCS data generated at the McGill 
University HTS laboratory (Figure 1), Chemistry Department of Princeton University (Figure 2), 
McMaster University laboratory - Data screened for McMaster Data Mining and Docking 
Competition (Figure 3), as well as those provided by the largest public HTS/HCS database, 
ChemBank, maintained by Harvard University’s Broad Institute (Figure 4). 
 
SCREENING TECHNOLOGIES and RELATED BIASES 
 
HTS and HCS technologies and their subcategories 
In this review, we focus on the two most widely used screening technologies: High-throughput 
screening (HTS) and high-content screening (HCS). In a typical HTS/HCS primary assay, the 
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selected library of chemical compounds is screened against a specific biological target to 
measure the intensity of the related inhibition or activation signal [8]. The size of the compound 
library can vary from hundreds to millions of items. Compounds are allocated across disposable 
microtiter plates of different sizes, typically including 96, 384 or 1536 wells. Well locations 
within a plate follow a rectangular matrix pattern. Each compound is usually placed in a single 
well. A suitable biological target culture (e.g., cells or a bacterial enzyme) is then added to each 
well of the plate. It is common to conduct unreplicated HTS experiments, although, as we show 
next, it is much more appropriate to obtain at minimum duplicate measurements. Processing the 
assay plates by HTS robotic equipment consists of a number of experimental wet-lab steps, 
including incubation, rising, and reagent additions to the biological culture of interest. Once the 
incubation period is over, the plates are scanned to obtain measures of biological activity 
characterizing the selected compounds. It is worth noting that the obtained raw activity levels 
depend not only on putative biological activity, but also on systematic and random errors 
affecting the given screen. Data analysis steps, including statistical procedures for data 
normalization and data correction, should then be carried out to identify hits.  
 
The increasing capacity of computer storage devices along with improvements in automation 
have allowed the use of HTS technologies to achieve resolution at the cellular level [9]. This 
related technology is called high-content screening (HCS). HCS is a screening method with 
multiple readouts that is based on microscopic imaging from a cell-based assay [10]. HCS 
obtains detailed information of cell structure by extracting multicolor fluorescence signals. HCS 
has three advantages relative to other screening techniques: (a) Cell-based analysis achieves high 
physiological correspondence, especially regarding drug screening; (b) Single cell analysis 
captures the heterogeneity of cell populations as well as the related individual response to 
treatments; (c) HCS generally has low false-positive and false-negative rates [11]. Thus, HCS 
technologies are commonly used in all areas of contemporary drug discovery, including primary 
compound screening, post-primary screening capable of supporting structure–activity 
relationships, early evaluation of ADME properties and complex multivariate drug profiling 
[12]. The Mytocheck [13] and ChemBank [14] databases are among the rare online resources 
containing publically available HCS data. 
 
Different subcategories of HTS and HCS technologies exist, depending on the target of interest. 
They comprise altering protein function using small molecules, increasing gene function using 
cDNA libraries and manipulating gene function using RNAi.  
 
(1) Small molecules: A “small molecule”, which can be either natural or artificial, is defined in 
pharmacology as a molecule associated with a particular biopolymer – for example a nucleic 
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acid or a protein [15]. There is currently a significant interest in extending efforts to discover 
small molecules targeting proteins encoded in the genomes of humans and pathogenic organisms 
[16]. Furthermore, small-molecule screening technologies have applications in other areas of 
drug discovery, such as target validation, assay development, secondary screening, 
pharmacological property assessment and lead optimization. The combination of principles of 
molecular pharmacology with modern high-throughput [4] and high-content [17] technologies is 
critical for the success of these discoveries.  
 
(2) cDNA library: High quality, full-length cDNA libraries are essential for discovery and 
validation of novel drug targets in functional genomic applications [18]. The discovery of 
reverse transcriptase permitted the transformation of unstable mRNA molecules into stable 
complementary DNA (cDNA) molecules. A comprehensive review of cDNA HCS can be found 
in [19], and that of cDNA HTS in [5, 20]. 
 
(3) RNA interference (RNAi): In the past decade, RNA interference (RNAi) has made great 
progress, evolving from a biological phenomenon into an effective method of drug discovery 
[21]. The two main advantages of RNAi screens compared to classical genetic screens are: (a) 
sequences of all identified genes are instantaneously identified and (b) lethal mutations are 
simple to determine because mutant recovery is not required [22]. The four types of RNAi 
reagents currently used in cell-based HTS are the following: dsRNAs, siRNAs, shRNAs and 
endoribonuclease-prepared siRNAs (esiRNAs) [23]. An important issue in genome-wide RNAi 
investigation is to combine both experimental and computational approaches to obtain high-
quality RNAi HTS assays and to overcome off-target effects [24-26]. A recent review by Knapp 
and Kaderali focuses on the analysis of RNAi HCS data and presents an approach for statistical 
processing of high-content microscopic screens [27]. 
 
Systematic error in screening technologies 
As with all biotechnologies, screening data are prone to both random and systematic errors. 
Random error, which varies among measured HTS compounds, lowers screening precision and 
likewise affects false positive and false negatives rates. Its adverse effects can be greatly 
minimized by obtaining at least duplicate measurements [28]. Systematic error (i.e., systematic 
or spatial bias) can be defined as the systematic under or over-estimation of measurements taken 
at the same plate or assay location [29]. Systematic errors can be the cause of nonspecific 
phenotypes in specific well, row or column locations and thus lead to higher false positive and 
false negative rates [7, 30]. Its adverse effects can be minimized by the application of data 
correction methods and study design procedures such as randomization and blocking [8, 31]. 
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Systematic error can be due to various technological and environmental factors, such as robotic 
failure, reader effect, pipette malfunctioning or other liquid handling anomalies, unintended 
differences in compound concentration related to agent evaporation, variation in the incubation 
time or temperature difference, as well as lighting or air flow abnormalities present over the 
course of the screening campaign [32, 33]. Thus, bias causing systematic under- or over-
estimation of biological activity measurements can cause some inactive compounds to be 
incorrectly identified as hits (i.e., false positives) and some active compounds to remain 
undetected (i.e., false negatives). Systematic error can be well, row or column dependent. It can 
affect compounds placed either to the same well, row or column location over all plates of the 
assay (i.e., assay-specific error) or those located in a particular row or column of a single plate 
(i.e., plate-specific error) [34]. 
 
Some specific positional effects appearing in HTS/HCS screens as a consequence of bias are 
summarized below. One often overlooked hurdle of HTS technologies is the batch effect [35]. A 
batch effect, i.e., bias present in some continuous subsets of the data and absent in others, occurs 
when some continuous groups of plates are affected by laboratory conditions which vary during 
the experiment. Although batch effects are hard to detect in low-dimensional assays, HTS 
technologies provide enough data to detect and remove them [35]. The edge effect, also called 
border effect, is another type of systematic error that consists in systematic under or over-
estimation of the measurements located on the plate's edges. Carralot et al. [36] indicated that 
although most repetitive errors in RNAi HTS can be generally controlled, some biases, such as 
edge effects, cannot be easily corrected due to well-to-well discrepancies inherent in the spatial 
structure of the plate. The cause of this effect is often unclear but medium evaporation or uneven 
treatment of the entire plate surface might be contributing factors [37]. Similarly to the plate-
specific edge effect, a more general assay-specific row, column, or well location effects can 
occur in both HTS and HCS screens when the data located in a particular row, column or well 
location are systematically over or under-estimated across all the plates of the assay. On the 
other hand, a systematic intra-image bias, consisting of the microscope-related errors, arises 
while capturing images in HCS. One of the issues here is a non-uniformity of background light 
intensity distribution, which is a slowly varying and systematic change of the spatial distribution 
of light in images. Such an effect can add or subtract intensities at any pixel location, thus 
affecting cell segmentation and florescence measurements, which, in turn, affect data 
quantification and statistical analysis [38]. 
Cell population context can also create systematic bias in high-content cellular screens and thus 
significantly influence results of HCS campaigns [39]. A method allowing for normalizing and 
scoring statistically microscopy-based RNAi screens has been recently proposed [40]. This 
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method exploits individual cell information of hundreds of cells per knockdown. The application 
of the proposed method and software [40] led to the identification of new host dependency 
factors of the hepatitis C and dengue viruses as well as to higher reproducibility of results of the 
screening experiments. 
 
Figure 1a illustrates the presence of edge effects (e.g., the measurements in column 2 are 
systematically overestimated) in the Harvard 164-plate assay [29, 41]. This assay consists of a 
screen of compounds inhibiting the glycosyltransferase MurG function of E. coli. Here, the 
binding effect of MurG to a fluorescent (fluorescein-labeled) analogue of UDP-GlcNAc was 
estimated. In this example, the threshold of μ–2σ was applied to identify hits. The HTS Corrector 
software [42] was used to calculate raw (Figure 1a) and B-score corrected (Figure 1b) hit 
distribution surfaces (i.e., a hit distribution surface gives the number of hits per well location 
found over all plates of the assay). The edge effect observed in column 2, and partially in row V, 
in the raw data was successively eliminated by the B-score procedure [3].  
 
Figure 1 
 
Similarly, image non-uniformity bias in HCS can be approximated and corrected by combining 
multiple images to generate a single image with an expected random spatial distribution of 
intensity values [38]. Such an approximation represents the overall effect of bias on the imaging 
field estimated using an image-averaging technique [43]. This positional bias can be detected by 
comparing the center of the image to its edges. In most cases, there is at least a two-fold increase 
in brightness between center and edges. Figure 2 illustrates non-uniformity bias present in a (96-
well x 4-field) HCS plate of microtubule polymerization status screened in the HCS laboratory 
of McGill University.  
 
Figure 2 
 
METHODS and RESULTS 
 
Data randomization and use of controls 
The primary aim of statistical practice consists in estimating experimental error, and in the case 
of systematic error, in reducing the negative effect of this error [44]. Experimental design and 
statistical analysis methods should be applied to accomplish these objectives, although often 
underused in screening practice [31]. A fundamental approach for error reduction in 
experimental design must include control and randomization techniques [45]; R.A. Fisher 
introduced the concept of randomization in which experimental units are assigned to groups or 
treatment in a manner that the probability of assignment to any particular group or treatment is 
equal and unbiased [46]. The main advantage of randomization in screening technologies is that 
randomized experimental units can distribute the error in a way that does not introduce 
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discrepancies to the experiment [31,47,48]. Thus, order of plate processing and compound 
placements both within each plate and across replicate plates of HTS/HCS assays should be 
randomized in order to reduce the impact of systematic bias on the outcome of screening 
experiments. 
 
Controls contain compounds with well-known biological activity. Positive controls provide 
maximum possible activity measurements and negative controls provide minimum possible 
activity measurements. Controls are used in control-based normalization methods to render the 
screening data comparable across different plates and to establish assay background levels. 
Ideally, controls should be located randomly within plates, but in practice, only the first and the 
last columns of the plate are typically available for controls. The related systematic edge effect 
can be reduced by alternating the positive and negative controls in the available wells, so that 
they appear equally on each of the plate's rows and columns [8]. If the edge effect affects the 
control wells, it will also affect all of the plate's measurements because they are normalized 
relative to the control activities. Randomization of the position of compounds in the replicated 
experiments is also very important, but unfortunately, is often limited due to practical 
considerations when automatic spotting approaches or some of the available statistical pipelines 
(e.g., cellHTS in BioConductor [49]) not supporting control randomization are used. RNAi 
controls generally exhibit more inter-well variability than small molecule controls because of 
variations in transfection efficiencies [50]. Cell-based biological controls are especially 
problematic because cell clumping or evaporation within different plate areas can lead to 
different growth conditions and thus to position-related bias [8, 36]. 
 
Advantages of replicated measurements  
Replicates offer the twin advantage of obtaining a greater precision of activity measurements and 
that of estimating the measurements variability [8]. The use of replicates allows one to reduce 
the uncertainty associated to a single measurement (i.e., standard error of the mean), as indicated 
in Formula 1:
 
 
%,11100 




 
n  
(1) 
where n is the number of replicates. Thus, carrying out two replicated screens reduces 
imprecision by 29%; carrying out three replicated screens reduces impression by further 13%; 
and, carrying out four replicated screens reduces the impression by additional 8% (i.e., 
eliminating in total 50% of imprecision associated with a single measurement). Therefore, the 
replicates make minimally and moderately active compounds simpler to detect. Two types of 
replicates exist: technical and biological ones [51]. Technical replicates, which address the 
variability of the process, are repeated measurements of the same sample that represent 
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independent measures of the random noise associated with equipment or protocols. Biological 
replicates, which mainly address the variability of the population but also reflect the variability 
of the process, are separate biological samples that were treated using the same protocol. When 
the sample population is unknown or has a higher variability, more biological replicates are 
needed. Increasing the number of technical replicates is important for a more variable technical 
protocol or when new screening equipment is used. Generally, biological variability is 
considerably greater than technical variability, so it is to our advantage to commit resources to 
sampling biologically relevant variables [51]. When planning for replication, researchers have to 
determine the proportion of variability induced by each experimental step to design statistically 
independent replicates and distribute the capacity for replication of the experiment across steps. 
Recognizing that obtaining even the minimal requirement of two replicates can be prohibitively 
expensive for some screens, Murie et al. [52] introduced the single assay-wide variance 
experimental (SAVE) design which can generate statistical tests of biological activity based on 
replication of only a small subset of plates.  
 
Figure 3 illustrates the presence of the batch effect in the McMaster Test dataset including the 
original and replicated sets of plates [53]. The McMaster Test assay consisted of a sequence of 
625 plates, each of which was screened twice (8x12-well plates were used; the first and the last 
columns of each plate contained controls – these columns are not displayed here; the remaining 
80 wells contained different compounds meant to inhibit the E. coli's dihydrofolate reductase). 
The well (8, 9) (i.e., well (H,10) – according to McMaster annotation; it is highlighted by a green 
box in Figure 3) displays a hit only in the replicated plates R1, R2, R3, R4, R5, R6, R7, R9 and 
R10, but not in the original plates 1, 2, 3, 4, 5, 6, 7, 9 and 10. This batch effect is absent in the 
replicated plate R8 and disappears starting from the replicated plate R11. Three of the hit 
compounds: MAC-0120363 (plates 1 and R1), MAC-0121481 (plates 3 and R3) and MAC-
0121668 (plates 5 and R5) were initially recognized as Average Hits by the McMaster 
competition organizers (the list of average hits contained 96 compounds whose average 
measurements, computed over the original and replicated screens, were lower than or equal to 
75% of the reference control average), but all of them were then rejected as false positives when 
the dose-response relationship analysis of the selected compounds was carried out [53]. It is 
worth noting that only 96 of 50 000 screened compounds in this assay were recognized as 
Average Hits.  
 
Figure 3 
Identification of hits  
The identification of hits is the primary goal of any HTS/HCS campaign. Some screeners select 
as screening positives a fixed number, or a fixed percentage, of top scoring compounds. 
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Compounds whose activity exceeds a fixed percent-of-control threshold may also be considered 
as hits [8, 54]. A wide range of more sophisticated hit identification techniques is available 
nowadays. Birmingham and colleagues [50] reviewed the existing hit selection methods, which 
can be classified as small-molecule derived methods and RNAi-specific techniques. Small-
molecule derived methods include: selection of samples whose screening activity exceeds a fixed 
threshold, which usually equals mean - 3 standard deviations for inhibition assays and mean + 3 
standard deviations for activation assays [8]; a robust to outliers improvement of the previous 
approach, using median instead of mean and median absolute deviation instead of standard 
deviations [55]; for assays using replicated measurements, the difference in means between 
replicates for each condition can be assessed with multiple t-tests [50]; finally, the Random 
Variance Model (RVM), which uses a weighted average of the compound-specific variance and 
an estimate of the typical variance of all of the compounds, has shown to be appropriate for 
small molecule HTS data with performance superior to that of standard t-tests [56, 8]. RNAi-
specific techniques include: quartile-based hit identification procedure, which establishes upper 
and lower hit selection thresholds based on number of interquartile ranges (i.e., above or below 
the first and third quartiles of the data) [57]; an accurate Strictly Standardized Mean Difference 
(SSMD) method, which computes the ratio between the difference of the means and the standard 
deviation of the difference between positive and negative controls [58]; and, the redundant 
siRNA Activity (RSA) analysis method, designed for screeners interested in information about 
multiple RNAi reagents tested for each gene, which assigns p-values to all reagents of a single 
gene [59]. 
 
Data normalization techniques which correct for overall plate bias only 
Data normalization in HTS consists in data transformation allowing for data comparability 
across different plates of the same assay [50]. The following simple types of data normalization, 
which do not correct for spatial systematic biases, are commonly used in screening technologies.  
 
Control Normalization is a control-based normalization method using the measurements of both 
positive and negative controls (Formula 2).  
,ˆ
negpos
negij
ij
x
x





 (2) 
where ijx  is the raw measurement of the compound located in well (i, j), ijxˆ  is the normalized 
value of the raw measurement ijx , pos  
is the mean of positive controls of the plate and neg  is 
the mean of negative controls of the plate. 
 
Median Percent Inhibition (MPI) normalization is carried out as follows (Formula 3): 
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,1100ˆ
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(3) 
where med is the median of all measurements of the plate. 
 
Z-score normalization is defined as follows (Formula 4):  
,ˆ



ij
ij
x
x
 
(4) 
where   and   are, respectively, the mean and the standard deviation of all measurements of 
the plate.  
 
Robust Z-score normalization can account for different scale and variability effects across HTS 
plates. It is less likely to produce biased scores because of outlying values of highly active 
compounds. Robust Z-score normalization is similar to Z-score except that the median is used 
instead of the mean and the median absolute deviation (MAD) is considered instead of the 
standard deviation to obtain the outlier resistant dispersion estimates (Formula 5): 
,ˆ
MAD
medx
x
ij
ij


 (5) 
where MAD is the median absolute deviation of measurements of the plate. 
 
Systematic error detection tests 
Several error correction methods and software have been recently developed to minimize the 
impact of systematic bias [7]. These methods and software should, however, be used with 
caution. Makarenkov et al. [33] demonstrated that systematic error correction methods can 
introduce systematic bias when applied on error-free HTS data. The introduced bias may be less 
important as in the case of the well correction procedure [33] or very important as in the case of 
the B-score method [3]. Thus, the presence or absence of systematic bias in raw HTS data must 
be first confirmed by the appropriate statistical tests [7, 60-62]. Systematic error detection tests 
that work well with screening data are summarized below. 
 
Welch's t-test: This test is based on the classical two-sample Welch's t-test for the case of 
samples with various sizes and unequal variances [60]. Two variants of this test can be 
considered in the framework of HTS/HCS analysis. The first variant concerns its application to 
each row and each column of every plate of the assay. The second variant concerns its 
application to the assay’s hit distribution surface. The measurements of the given plate (or of the 
hit distribution surface) are subdivided into two samples: the first sample contains the 
measurements of the tested row or column, while the second sample includes the remaining 
plate’s measurements. The null hypothesis, H0, here is that the considered row or column does 
not contain systematic error. For the two considered samples, 1S  with 1N  elements and 2S  with 
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2N  elements, the two sample variances, 
2
1s  and 
2
2s , are first calculated. Welch's t-test statistic 
can then be computed using Formula 6: 
,
2
2
2
1
2
1
21
N
s
N
s
t




 (6) 
where 
1  is the mean of sample 1S  and 2  is the mean of sample 2S . The t-test value is then 
compared to the critical value corresponding to the chosen statistical significance level  in order 
to decide whether H0 should be rejected or not. Welch's t-test is usually applied when the data 
are normally distributed but the sample variances may differ. However, for moderately large 
samples and a one-tailed test, this statistic is relatively robust to violations of the normality 
assumption. 
 
2 goodness-of-fit test: This test can be used to establish the presence or absence of systematic 
error in a hit distribution surface [7]. The null hypothesis H0 here is the same as in Welch's t-test. 
The rejection region of H0 is    )(
2 CP , where C  is the χ
2
 distribution critical value, 
corresponding to the chosen parameter   and the number of degrees of freedom. For a hit 
distribution surface with RN  rows and CN  columns, one can test the presence of systematic 
error in a given row r by calculating the 2r statistic (Formula 7):  




CN
j
rj
r
E
Ex
1
2
2
)(
 ,
 
(7) 
where rjx  is the j
th
 value in row r,  is the hits count of the whole hit distribution surface divided 
by the number of wells ( RN x CN ). The number of degrees of freedom here is RN -1. 
In the same way, the columns of the hit distribution surface affected by systematic error can be 
tested by computing the test statistic 2c  (Formula 8): 
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(8) 
The number of degrees of freedom here is CN  - 1. 
Systematic error affecting a particular well location (i, j) and appearing along all plates of the 
assay can be also identified by computing the χ2 statistic [7] (Formula 9): 
.
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1 1
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(9) 
The number of degrees of freedom here is RN x CN -1. The following main assumptions should 
be met for this test: (a) the observations are independent of each other, and (b) the expected hits 
count in each well location of the hit distribution surface should be at least 5. 
 
Kolmogorov-Smirnov test preceded by Discrete Fourier Transform: This method consists of 
Discrete Fourier Transform (DFT) [63] signal analysis method followed by the Kolmogorov-
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Smirnov (KS) test [64]. It is included in some commercial software intended to detect systematic 
error in screening data (e.g., in the Array Validator program described in [65]). The KS test is a 
non-parametric test having the advantage of making no assumption about the distribution of data. 
As recently has been shown, Welch's t-test usually outperforms the
2 goodness-of-fit test and 
the KS test preceded by DFT in the context of HTS analysis [7]. A comprehensive simulation 
study involving artificially generated HTS data was carried out to compare the three above-
mentioned tests in a variety of practical situations. The success rate of the t-test was usually 
above 90%, regardless the plate size, the type, and the magnitude of systematic error, whereas 
the values of Cohen's kappa coefficient for this test suggested its superior performance, in the 
case of large plates and high level of systematic bias [7]. 
 
Mann-Whitney-Wilcoxon (MWW) test: This test verifies whether two samples of measurements 
are identical. First, a suitable Type I error probability, α, is chosen for the test and the data in two 
samples of interest, X1 and X2, are ranked. The MWW test [61] is based on Formula 10: 
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where N1 and N2 are the sizes of samples X1 and X2, and  


1
1
11
N
k
kXRankW  is the sum of the 
ranks of the first sample measurements. The correction factor, C, equals 0.5, if the rest of the 
numerator of z is negative, or equals -0.5, otherwise. The standard deviation, W , is determined 
using Formula 11: 
 
.
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NNNN
W  
(11) 
As this is a non-parametric test, it does not make assumptions about the underlying data 
distribution. 
Rank products test: Consider the expression levels of n genes for k1 independent replicates in 
sample X1, and k2 independent replicates in sample X2. Let Xijm be the expression level of the i
th
 
gene in the j
th
 replicate of the m
th
 sample, where ,1 ni  mkj 1 , .21  m  By ranking the 
expression levels X1jm, X2jm, …, Xnjm within each replicate j, we form the vectors Rijm = rank(Xijm), 
where nRijm 1  and .21  m  The suitable two-sample version of Breitling’s Rank products 
statistic, RP, for the i
th
 gene can then be calculated by using Formula 12 [62, 66]: 
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(12) 
Genes associated with sufficiently large or small RPi values are marked for further consideration. 
A few assumptions for this non-parametric test are the following [66]: (a) relevant expression 
changes affect only a minority of genes, (b) measurements are independent between replicated 
plates (or screens); (c) most changes are independent of each other, and (d) measurement 
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variance is about equal for all genes. The MWW and Rank products tests have been successively 
applied in the RNAi screening [67, 68]. 
 
To estimate the magnitude of systematic bias in experimental HTS data, we carried out a series 
of tests using the data extracted from the largest public HTS/HCS database, ChemBank [14]. 
Figure (4a) reports the average row and column systematic error rates in raw HTS measurements 
obtained from 41 HTS assays (735 plates in total) aimed at the inhibition of the E. coli 
bacterium. In this analysis, we considered all HTS assays related to the E. coli inhibition, that 
were available in ChemBank as to April 2014. The presented results were obtained by using 
Welch’s t-test (Equation 6) with different values of the parameter α = 0.01, 0.025, 0.05, 0.075 
and 0.1. The null hypothesis here was that the considered row or column did not contain any 
systematic bias. Figure (4b) illustrates the average hit distribution surface error rates for raw 
data. The presence of systematic errors in an assay can be determined through the analysis of its 
hit distribution surface depicting the total hit counts per well location over all plates of the assay 
[33]. Thus, we estimated over all assay's plates the number of measurements with the values 
lower than the µ-cσ threshold, where the mean value µ and the standard deviation σ were 
computed separately for each plate; the constant c was gradually set to 2.5, 3.0 and 3.5 to 
account for the most popular hit selection thresholds. Here also, Welch’s t-test was used to 
determine the presence or absence of systematic error. Similarly, Figure (4c) presents the 
average row and column error rates for the background-subtracted measurements for the same 41 
HTS assays (background-subtracted data were also extracted from ChemBank), and Figure (4d) 
shows the average hit distribution surface error rates for the background-subtracted data. The 
Matlab 8.2 package [69] was used in our computations. The presented graphics suggest that the 
row and column systematic bias is common to experimental HTS assays (i.e., plate-specific 
error) – at least 30% of rows and columns in the raw data and 20% of rows and columns in the 
background-subtracted data were affected by systematic bias (Figure 4a and c). Moreover, 
systematic error is even more visible when analyzing hit distribution surfaces (i.e., assay-specific 
error) – at least 50% of raw hit distribution surfaces and 65% of background-subtracted hit 
distribution surfaces were affected by systematic error (Figure 4b and d). 
 
Figure 4 
 
Data normalization techniques which correct for plate-specific and assay-specific spatial 
systematic biases 
This section describes the statistical methods that are used for minimizing plate-specific and 
assay-specific (i.e., across-plate well-location bias) systematic biases in screening technologies. 
Most of these methods allow the correction of overall plate bias as well. 
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R-scores: This plate-specific correction method [70] relies on Formula 13: 
,ijpjpippijp rCRx    (13) 
where ijpx is the compound measurement in row i and column j
 
of plate p, p  is the mean of 
plate p, Rip is the row bias affecting row i of plate p, Cjp is the column bias affecting column j of 
plate p and rijp is the residual in well (i, j) of plate p. These parameters can be estimated using, 
for example, the rlm function from the MASS package of the R language [71]. The R-scores are 
the model's residuals rescaled by dividing them by the standard deviation estimate of the 
regression function. 
 
B-scores: This method corrects the raw plate measurements by iteratively eliminating possible 
row and column positional biases [3]. The statistical model for the raw measurement xijp is 
similar to Formula 13. The B-scores method relies on a two-way median polish (MP) procedure 
[72] carried out separately for each plate of the assay to obtain the estimates of xijp, μp, Rip and 
Cjp. The residual rijp of the measurement in well (i, j) is then calculated as the difference between 
the raw measurement xijp and its fitted value ijpx
~ : rijp = xijp− ijpx
~ . Finally, the obtained residuals are 
divided by the median absolute deviation of plate p (Formula 14): 
,
p
ijp
MAD
r
B-score  }.|)({| where ijpijpp rmedrmedMAD   (14) 
A variant of the B-scores method used in HCS [73] considers the mean true activity value, μijp, in 
well (i, j) in Formula (13), instead of μp.  
 
Well correction: This assay-specific correction method proceeds by data normalization along the 
well locations of the assay [33, 42]. At first, Z-score normalization (Formula 4) is performed 
within each plate of the assay. The following two steps are then carried out. First, a linear least-
square approximation is performed for the measurements of each well location of the assay (this 
well-specific approximation is done across all plates of the assay). Second, Z-score 
normalization of the fitted measurements obtained from regression is carried out independently 
for each well location of the assay (still across all plates of the assay). 
 
Robust well correction: This is another assay-specific data correction procedure. Each plate is 
normalized using robust Z-scores (Formula 5) and then the entire set of plates is ordered by date 
of processing and a robust regression line is fit to the data. This fitting is carried out 
independently for each well location across all plates of the assay as in the Well correction 
method. The obtained normalized residuals are considered as final corrected scores [31]. 
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Diffusion Model: This model is designed to eliminate the edge effect in the HTS RNAi screens 
[36]. The process-specific diffusion process is described by the following parabolic differential 
equation (Formula 15): 
 
 ,,,
~,,
~
tjibc
t
tjib



 
(15) 
where  t,j,ib~  is the evaluated spatiotemporal diffusion field in well (i, j) at time t (i.e., evaluated 
systematic bias), c is the diffusion coefficient and   is the Laplacian operator. The following 
boundary conditions are considered (Formula 16):  
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(16) 
where 0U  and 1U are the model's positive parameters; the model also assumes that: 
 at the initial time t = 0 of the dispensing, there is no edge effect on the given plate;  
 the effect strength depends on a physical difference between the inside parameter   and 
outside parameter \2Z  of the given plate. 
 
Loess correction method: The loess error correction method evaluates the plate's row and column 
effects by fitting a loess curve to each row and column of the given plate [74, 75]. The loess 
correction is defined by Formula 17: 
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(17) 
where ijx is the raw measurement in well (i, j), ijx
~ is the adjusted measurement in this well, ir  is 
the mean of the fitted loess curve for row i, jc is the mean of the fitted loess curve for column j, 
ijr  is the value of the fitted row loess curve for row i and column j, and ijc  is the value of the 
fitted column loess curve for row i and column j.  
 
Median Filter: The median filter method [76] adjusts the intensity value of the given well (i, j) 
using the median of the intensity values of the nearby wells. First, a row median filter, whose 
filter window includes the wells located on the same row i, within k wells of well (i, j), is carried 
out. Second, a standard median filter procedure, its filter window includes the wells located 
within l wells of well (i, j), is applied. The constants k and l usually equal 3 for the 1536-well 
plates, and 1 and 2 for the 96-well plates. The method relies on Formula 18 to compute the 
adjusted measurements: 
,~









wij
p
med
med
ij
x
ij
x
 
(18) 
where pmed  is the median intensity of plate p and wijmed  is the median intensity of wells 
included in the filter window of well (i, j).  
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SPatial And Well Normalization (SPAWN): This two-step procedure gradually applies a trimmed 
mean polish procedure on individual plates in order to minimize row and column systematic 
effects [77]. The considered statistical model relies on Formula 13. Then, a well normalization 
step is carried out to determine spatial bias template, SBTij, which is the median of the scores at 
well location (i, j) computed over all plates of the assay.
 
The spatial bias template scores are 
subtracted from the scores obtained by the median polish procedure:
 
.ˆ ijijpijp SBTrr   Finally, the 
resulting scores are rescaled by dividing them by the median absolute deviation of the plate. 
Thus, SPAWN corrects for both plate-specific and assay-specific biases. 
 
Matrix Error Amendment (MEA) and Partial Mean Polish (PMP): These algebraic methods are 
designed to modify only those rows and columns of the given plate that are affected by 
systematic bias [34]. MEA and PMP methods rely on prior information concerning the presence 
and absence of systematic error in the rows and columns of the given plate. Such information can 
be obtained using a specific version of Welch's t-test or the χ2 goodness-of-fit test (see previous 
section). One of the main advantages of the PMP method over MP and B-scores [3] is that PMP 
does not reduce the original data to residuals, keeping the corrected measurements on the same 
scale with the original ones. 
 
Table 1 reports the discussed data normalization techniques recommended for the analysis of 
HTS and HCS data along with the underlying assumptions regarding their practical application. 
 
Table 1 
 
Various plots that use robust statistical indices have been also suggested for detecting shifts and 
trends across time in large screening campaigns [3]. Systematic bias within plates can be 
detected with visualization methods such as 2-dimensional heat maps and 3-dimensional wire 
plots, although typical plate-specific bias patterns are more easily detected with auto-correlation 
plots that show the degree of correspondence between wells at various "lags" (e.g., adjacent or 
separated by one well) [31]. Finally and somewhat counterintuitively, screens with few active 
compounds should show low correlations between replicate plates; for these screens, scatterplots 
which show high correspondence between replicate plates indicate across-plate well-specific bias 
rather than good biological reproducibility [31]. 
 
DISCUSSION and CONCLUSION 
 
We reviewed current knowledge on systematic bias affecting raw data in HTS and HCS 
technologies. First, we discussed the causes of systematic bias and its impact on the selection of 
correct hits in HTS and HCS experiments. The main steps of HTS and HCS screening protocols 
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were presented along with the subcategories of screening technologies, including small 
molecule, cDNA and RNAi screens. Positional bias effects characteristic of screening 
technologies, comprising batch effects, edge effects and well location effects, were discussed in 
detail. We highlighted that randomization of experimental units and use of replicates can 
significantly reduce the magnitude of systematic error. Data normalization techniques which 
correct for overall plate bias were presented, followed by the description of systematic error 
detection tests specific to screening technologies. Finally, we discussed error correction methods, 
indicating under which assumptions and for which kind of spatial bias each of them should be 
used. In particular, we underlined the distinction between the plate-specific and assay-specific 
systematic biases and pointed out that data correction methods should be applied only if the 
presence of systematic bias was confirmed by the appropriate statistical tests. Otherwise, an 
unwanted bias can be introduced into error-free data. 
 
Figure 5 
 
In order to summarize our presentation, we describe here a general data pre-processing and 
correction protocol (Figure 5), which could be used as a guide by academic and industrial 
researchers involved in the analysis of current or next generation screening data. The first 
required step concerns general design of a screening campaign. The compound locations within 
each plate, as well as over all plates of the assays, should be randomized in order to reduce the 
impact of systematic bias on the outcome of screening experiments. Moreover, whenever the 
campaign funding allows, several replicates of the compound library should be screened. 
Replicated screens provide both a greater precision of activity measurements and the ability to 
assess measurement variability [8]. Once the assay measurements have been established, the 
appropriate data normalization procedure should be carried out to ensure the data comparability 
over different plates and screening conditions. Afterwards, systematic error detection tests 
should be carried out to confirm the presence or absence of systematic error in raw data (e.g., 
Welch’s t-test or χ2 goodness-of-fit test). In particular, these tests can be applied to identify: (1) 
positional effects of systematic error, including row, column and well location biases; (2) error 
specificity, including plate, batch and assay-specific biases; (3) type of systematic error, 
including additive (e.g., Robust well correction, SPAWN or PMP methods can be applied to 
eliminate this type of bias) and multiplicative (e.g., diffusion model can be applied to eliminate 
this type of bias) biases. If systematic error was not detected in the data, then no any correction 
method needs to be applied to them to avoid the risk of introduction of additional biases [7]. 
Otherwise, the appropriate error correction method, preferably including a success of control 
step, should be carried out. Once systematic bias is minimized, assay quality estimation and hit 
identification steps can be carried out. It is worth noting that the plate-specific correction 
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methods (e.g., PMP) can sometimes be applied in combination with the assay-specific correction 
methods (e.g., Robust well correction). First, Welch’s t-test can be carried out independently for 
each individual plate of the assay to detect the plate's rows and columns affected by systematic 
bias. The measurements affected by bias can be subsequently corrected by using the PMP 
method, which keeps the corrected data on the same scale with the original ones. Second, 
Welch’s t-test can be performed over the hit distribution surface of the entire assay. If the test 
identifies the presence of systematic bias on the surface, the Robust well correction procedure 
can be carried out to remove the assay-specific bias. An alternative solution to this problem 
could be provided by the methods which correct for both plate-specific and assay-specific biases 
(e.g., SPAWN). 
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Key Points 
 
 We reviewed current knowledge on systematic bias affecting experimental HTS and HCS 
data.  
 Study design issues and the way in which data are generated are crucial for providing 
unbiased screening results. Unfortunately, these key steps are often ignored by HTS 
practitioners. 
 Data correction methods should be applied only if the presence of systematic error has 
been confirmed by the appropriate statistical tests. 
 Discussed sources of systematic bias and presented statistical methods and software 
intended to correct experimental screening data provide a unifying framework when 
considering new screening technologies. 
 We presented a general data pre-processing and correction protocol which can be used as 
a guide by academic and industrial researchers involved in the analysis of current or next 
generation screening data. 
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Figure legends 
 
 
 
Figure 1: Systematic error in experimental HTS data (Harvard's 164-plate assay [41]). Hit 
distribution surfaces for the -2 hit selection threshold are shown for: (a) Raw data; (b) B-score 
corrected data. Well, row and column positional effects are illustrated. The data are available at: 
http://www.info2.uqam.ca/~makarenkov_v/HTS/home.php/downloads/Harvard_164.zip. 
 
Figure 2 Non-smoothed foreground (non-uniformity bias) for images of a single (96-well x 4-
field) HCS plate of microtubule polymerization status generated in the HCS laboratory of McGill 
University is shown. The data are available at: http://nadon-mugqic.mcgill.ca. 
 
Figure 3: Batch positional effect appearing in the McMaster Test assay screened during the 
McMaster Data Mining and Docking Competition [53]. The first 24 plates of the assay are 
shown (12 original and 12 replicated plates; the plate number is indicated on each plate; the 
replicated plates are indicated by the letter R). Each original plate is followed by its replicate. 
Hits are shown in blue. Green boxes emphasize well (8, 9) on each plate (i.e., well H10, 
according to the McMaster annotation) where the batch effect occurs. The data are available at: 
http://www.info2.uqam.ca/~makarenkov_v/HTS/home.php/downloads/McMaster_1250.zip. 
 
Figure 4: Proportion of rows and columns affected by systematic bias in 41 experimental HTS 
assays (735 plates in total; control wells were ignored) aiming at the inhibition of the 
Escherichia coli. Experimental data were extracted from the Harvard University HTS databank 
(i.e., ChemBank [14]). Here we show: (a) Overall row and column error rate for raw data; (b) hit 
distribution surface error rates for raw data; (c) overall row and column error rate for 
background-subtracted data; (d) hit distribution error rate for background subtracted data. The 
following hit selection thresholds were used to identify hits and establish hit distribution surfaces 
of the assays: µ-2.5σ (◊), µ-3σ (∆) and µ-3.5σ (○), where µ and σ are, respectively, the mean and 
standard deviation of the plate’s measurements. 
 
Figure 5: Recommended data pre-processing and correction protocol to be performed prior to 
the hit identification step in high-throughput and high-content screening. 
